News

Conference Coverage

Maintenance Senaparib Improved PFS Among Patients With Newly Diagnosed, Advanced Ovarian Cancer

10/25/2023

According to results from the phase 3 FLAMES study, maintenance senaparib in the first-line setting significantly reduced the risk of progression or death among patients with newly diagnosed, stage 3 to 4 high-grade serous or endometrioid...

According to results from the...

10/25/2023

Oncology

News

Hyperthermic Intraperitoneal Chemotherapy Plus Interval Cytoreductive Surgery Significantly Improved Long-Term Survival Outcomes in Advanced Ovarian Cancer

10/12/2023

Stephanie Holland ;

According to updated survival results from the phase 3 OVHIPEC-1 trial, the addition of hyperthermic intraperitoneal chemotherapy to interval cytoreductive surgery significantly improved long-term progression-free survival and overall...

According to updated survival...

10/12/2023

Oncology

News

Rechallenge With Olaparib Maintenance Improved PFS Among Patients With Previously Treated, Platinum-Sensitive Ovarian Cancer

10/10/2023

Stephanie Holland ;

Results from the OReO/ENGOT-ov38 trial demonstrated that rechallenging with olaparib in the maintenance setting improved progression-free survival among patients with previously treated, platinum-sensitive ovarian cancer, regardless of BRCA...

Results from the OReO/ENGOT-ov38...

10/10/2023

Oncology

News

Atezolizumab Added to Bevacizumab Plus Platinum-Based Chemotherapy Did Not Improve PFS Among Patients With Platinum-Sensitive Ovarian Cancer

09/19/2023

Stephanie Holland ;

According to results from the ATALANTE/ENGOT-ov29 study, the addition of atezolizumab to bevacizumab and platinum-based chemotherapy did not statistically improve PFS among patients with platinum-sensitive ovarian cancer.

According to results from the...

09/19/2023

Oncology

News

Maintenance Niraparib Extended PFS Among Patients With Advanced Ovarian Cancer

07/26/2023

Stephanie Holland ;

According to results from the phase 3 PRIME study, first-line, maintenance niraparib prolonged PFS with an individualized starting dose that was both safe and effective among patients with newly diagnosed, advanced ovarian cancer.

According to results from the...

07/26/2023

Oncology

News

Relacorilant Plus Nab-Paclitaxel Improved Survival, Response in Platinum-Resistant Ovarian Cancer

07/25/2023

Stephanie Holland ;

According to results of a phase 2 trial, intermittent relacorilant plus nab-paclitaxel improved PFS, DOR, and OS with similar ORR to that of nab-paclitaxel monotherapy among patients with pre-treated, recurrent, platinum-resistant ovarian...

According to results of a phase...

07/25/2023

Oncology

Conference Coverage

Durvalumab Plus Chemotherapy and Bevacizumab Followed By Triplet Maintenance in Newly Diagnosed Advanced Ovarian Cancer

06/15/2023

Amber Denham ;

Phase 3 data reveal treatment with durvalumab plus paclitaxel/carboplatin and bevacizumab followed by maintenance bevacizumab with durvalumab and olaparib significantly improves PFS in patients with newly diagnosed ovarian cancer without a...

Phase 3 data reveal treatment...

06/15/2023

Oncology

Conference Coverage

Mirvetuximab Soravtansine As Standard of Care for Folate Receptor Alpha-Positive, Platinum-Resistant Ovarian Cancer

06/04/2023

Allison Casey ;

According to a grade 3 study, mirvetuximab soravtansine resulted in improved progression-free survival and overall survival for patients with platinum-resistant ovarian cancer, compared to chemotherapy.

According to a grade 3 study,...

06/04/2023

Oncology

News

Olaparib Efficacy, Safety Unaffected by Old Age Among Patients With Ovarian Cancer

03/09/2023

Derek Cowsert ;

A study found that age did not affect the safety or efficacy of treatment with olaparib and bevacizumab for patients with ovarian cancer.

A study found that age did not...

03/09/2023

Oncology

News

Mirvetuximab Soravtansine Demonstrates Safety, Efficacy in Platinum-Resistant Ovarian Cancer With High Folate Receptor Alpha Expression

02/07/2023

Derek Cowsert ;

Study findings show mirvetuximab soravtansine yields promising results in efficacy and safety among patients with high folate receptor alpha expressing platinum-resistant ovarian cancer.

Study findings show mirvetuximab...

02/07/2023

Oncology

Recent News

News

Intraoperative Radiation Therapy May Improve Survival For Certain Patients With Recurrent Cervical or Endometrial Cancer

11/14/2024

Allison Casey ;

According to a retrospective study, there was an appreciable survival gain for well-selected patients with recurrent or persistent endometrial or cervical cancer who receive intraoperative radiation therapy.

According to a retrospective...

11/14/2024

Oncology

News

Amrubicin Plus Irinotecan Demonstrates Promising Efficacy, Safety for Chemotherapy-Naïve Patients With Extensive-Disease Small Cell Lung Cancer

11/14/2024

Stephanie Holland ;

According to results from the phase 2 LC 08-01 trial, amrubicin plus irinotecan demonstrated promising efficacy and safety among chemotherapy-naïve patients with extensive-disease small cell lung cancer.

According to results from the...

11/14/2024

Oncology

News

Addition of Bempegaldesleukin to Nivolumab Does Not Benefit Cisplatin-Ineligible Patients With First-Line Advanced Urothelial Carcinoma

11/13/2024

Stephanie Holland ;

Results from the phase 2 PIVOT-10 trial demonstrated that the addition of bempegaldesleukin to first-line nivolumab did not improve outcomes for cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma.

Results from the phase 2...

11/13/2024

Oncology

News

Mirdametinib for Adult and Pediatric Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

11/12/2024

Allison Casey ;

According to a phase 2b trial, mirdametinib demonstrated significant confirmed objective response rates with deep and durable reductions of volume of target plexiform neurofibromas and clinically meaningful improvements to health-related...

According to a phase 2b trial,...

11/12/2024

Oncology

News

Epirubicin Plus Cyclophosphamide and Docetaxel Reduces Long-Term Risk of Recurrence for Patients With TOP2A Normal Early Breast Cancer

11/12/2024

Stephanie Holland ;

According to final results from the DBCG 07-READ trial, the addition of epirubicin to cyclophosphamide and docetaxel reduced long-term risk of breast cancer recurrence among patients with TOP2A normal early breast cancer.

According to final results from...

11/12/2024

Oncology

News

Pembrolizumab Plus Chemotherapy For Patients With High-Risk Endometrial Cancer

11/11/2024

Allison Casey ;

According to results from a phase 3 trial, pembrolizumab plus chemotherapy did not improve DFS among patients with high-risk endometrial cancer. However, there may be a benefit among patients with mismatch report-deficient disease.

According to results from a...

11/11/2024

Oncology

FDA Approval

FDA Grants Approval to Obecabtagene Autoleucel for R/R B-Cell Precursor Acute Lymphoblastic Leukemia

11/08/2024

On November 8, 2024, the FDA approved CD19-directed genetically modified autologous T cell immunotherapy obecabtagene autoleucel for the treatment of patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.

On November 8, 2024, the FDA...

11/08/2024

Oncology

News

Naporafenib in Combination With Rineterkib or Tremetinib for KRAS- or BRAF-Mutant Non-Small Cell Lung Cancer

11/07/2024

Allison Casey ;

While naporafenib plus rineterkib and naporafenib plus trametinib both had acceptable safety profiles, antitumor activity was limited among patients with KRAS-/BRAF-mutant non-small cell lung cancer.

While naporafenib plus...

11/07/2024

Oncology

News

Addition of Concurrent Thoracic Radiotherapy to First-Line TKI Therapy Improves Survival for Patients With EGFR-Mutated Non-Small Cell Lung Cancer

11/06/2024

Stephanie Holland ;

According to results from a phase 3 trial, the addition of concurrent thoracic radiotherapy to first-line icotinib improved survival among patients with EGFR-mutated oligo-organ metastatic non-small cell lung cancer.

According to results from a...

11/06/2024

Oncology

News

Ipilimumab After PD-1 Inhibition Failure Among Patients With Metastatic Melanoma

11/05/2024

Allison Casey ;

A single-center real-world study found the use of ipilimumab in the second-line was an effective therapy for patients with metastatic BRAF/NRAS-wildtype metastatic melanoma without brain metastases.

A single-center real-world study...

11/05/2024

Oncology